Search - tctmd.com

Displaying 61 - 80 of 141

Sort: Relevancy | Date

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

News Daily News

Latest Statin Risk-Benefit Analysis: More Harm Than Good?

Yael L. Maxwell

July 15, 2021

News Daily News

OMT Boosts Survival in Revascularized Patients at 10 Years

Michael O'Riordan

June 29, 2021

News Daily News

Less Cancer Among HF Patients Taking Statins, Registry Shows

Michael O'Riordan

June 23, 2021

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

News Opinion CV Team Dispatch

May 2021 News Roundup

L.A. McKeown

May 01, 2021

News Daily News

Experts Fear Coronary CT Advice for Patients Misses the Mark

Michael O'Riordan

March 19, 2021

News Daily News

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

Michael O'Riordan

December 07, 2020

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

News Daily News

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Yael L. Maxwell

August 27, 2020

News Daily News

Could Statins Curb Fatal or Severe COVID-19? Some Clues

Michael O'Riordan

August 14, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Obesity and Aortic Stenosis: Genetic Analysis Hints at Causal Link

Yael L. Maxwell

January 13, 2020

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

Advertisement

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Latest Statin Risk-Benefit Analysis: More Harm Than Good?

OMT Boosts Survival in Revascularized Patients at 10 Years

Less Cancer Among HF Patients Taking Statins, Registry Shows

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

May 2021 News Roundup

Experts Fear Coronary CT Advice for Patients Misses the Mark

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Could Statins Curb Fatal or Severe COVID-19? Some Clues

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Obesity and Aortic Stenosis: Genetic Analysis Hints at Causal Link

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content